Keratinocyte unresponsiveness towards interleukin-10: Lack of specific binding due to deficient IL-10 receptor 1 expression

Experimental Dermatology

Volumn 12, Issue 2, 2003, Pages 137-144

  Seifert, Martina ^b   Gruenberg, Beate H ^a   Sabat, Robert ^a,b   Donner, Peter ^a   Gruetz, Gerald ^b   Volk, Hans Dieter ^b   Wolk, Kerstin ^a   Asadullah, Khusru ^a  

^a BAYER PHARMA AG   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Cytokines; Immunomodulation; Receptors

Indexed keywords

BIOTIN; CYTOKINE; GAMMA INTERFERON; GENE PRODUCT; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 10 RECEPTOR 1; INTERLEUKIN 10 RECEPTOR 2; MESSENGER RNA; RECOMBINANT INTERLEUKIN 10; SUPPRESSOR OF CYTOKINE SIGNALLING 1; SUPPRESSOR OF CYTOKINE SIGNALLING 3; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING KINETICS; CELL FUNCTION; CELL LINE; CHILD; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG LABELING; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG TARGETING; FLOW CYTOMETRY; HOMEOSTASIS; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMEDIATE EARLY GENE; KERATINOCYTE; PHARMACOLOGICAL BLOCKING; PREPUCE; PROTEIN EXPRESSION; RECEPTOR POTENTIAL; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SCATCHARD PLOT; SKIN CELL; WESTERN BLOTTING;

CARRIER PROTEINS; CELLS, CULTURED; GENE EXPRESSION; HUMANS; INTERLEUKIN-10; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KERATINOCYTES; PROTEINS; PSORIASIS; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-10; RECOMBINANT PROTEINS; REPRESSOR PROTEINS; RNA, MESSENGER; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRANSCRIPTION FACTORS;

EID: 0037755320     PISSN: 09066705     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0625.2003.120203.x     Document Type: Article

References (26)

1. Michel G, Gailis A, Jarzebska-Deussen B et al. T.1,25-(OH)2-vitamin D3 and calcipotriol induce IL-10 receptor gene expression in human epidermal cells. Inflamm Res 1997: 46: 32-34.
2. Michel G, Mirmohammadsadegh A, Olasz E et al. Demonstration and functional analysis of IL-10 receptors in humanepidermal cells: Decreased expression in psoriatic skin, down-modulation by IL-8, and up-regulation by an antipsoriatic glucocorticosteroid in normal cultured keratinocytes. J Immunol 1997: 159: 6291-6297.
3. Asadullah K, Sterry W, Stephanek K et al. IL-10 is a key cytokine in psoriasis. J Clin Invest 1998: 101: 783-794.
4. Asadullah K, Döcke W D, Ebeling M et al. IL-10 treatment of psoriasis - Clinical results of A Phase II trial. Arch Derm 1999: 135: 187-192.
5. Asadullah K, Döcke W D, Sabat R V et al. The treatment of psoriasis with IL-10: Rationale and review of the first clinical trials. Expert Opin Invest Drugs 2000: 1: 95-102.
6. Asadullah K, Friedrich M, Hanneken S et al. Effects of systemic interleukin-10 therapy on psoriatic skin lesions: Histological, immunohistological and molecular biological findings. J Invest Dermatol 2001: 116: 721-727.
7. Reich K, Garbe C, Blaschke V et al. Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. J Invest Dermatol 2001: 116: 319-329.
8. Friedrich M, Döcke W D, Klein A et al. Immunomodulation by IL-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in psoriasis. J Invest Dermatol 2002: 118: 672-677.
9. Seifert M, Sterry W, Effenberger E et al. The antipsoriatic activity of IL-10 is rather caused by effects on peripheral blood cells than by a direct effect on human keratinocytes. Arch Dermatol Res 2000: 292: 164-172.
10. Becherel P A, LeGoff L, Ktorza S et al. Interleukin-10 inhibits IgE-mediated nitric oxide synthase induction and cytokine synthesis in normal human keratinocytes. Eur J Immunol 1995: 25: 2992-2995.
11. Enk A H, Katz S I. Contact sensitivity as a model for T-cell activation in skin. J Invest Dermatol 1995: 105 (Suppl. 1): 80S-83S.
12. Ohmen J D, Hanifin J M, Nickoloff B J et al. Overexpression of IL-10 in atopic dermatitis. Contrasting cytokine patterns with delayed-type hypersensitivity reactions. J Immunol 1995: 154: 1956-1963.
13. Boukamp P, Petrussevska R T, Breitkreutz D, Hornung J, Markham A, Fusenig N E. Normal keratinization in a spontaneously immortalized aneuoloid human keratinocyte cell line. J Cell Biol 1988: 106: 761-771.
14. Krebs D L, Hilton D J. SOCS: Physiological suppressors of cytokine signaling. J Cell Sci 2000: 113: 2813-2819.
15. Yasukawa H, Sasaki A, Yoshimura A. Negative regulation of cytokine signaling pathways. Annu Rev Immunol 2000: 18: 143-164.
16. Cassatella M A, Gasperini S, Bovolenta C et al. Interleukin-10 (IL-10) selectively enhances CIS3/SOCS3 mRNA expression in human neutrophils: Evidence for an IL-10-induced pathway that is independent of STAT protein activation. Blood 1999: 94: 2880-2889.
17. Donnelly R P, Dickensheets H, Finbloom D S. The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J Interferon Cytokine Res 1999: 6: 563-573.
18. Ito S, Ansari P, Sakatsume M et al. Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma- induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 1999: 93: 1456-1463.
19. Marttila A T, Laitinen Oh, Airenne K J et al. Recombinant NeutraLite Avidin: A nonglycosylated, acidic mutant of chicken avidin that exhibits high affinity for biotin and low non-specific binding properties. FEBS Lett 2000: 467: 31-36.
20. Tan C J, Indelicato S R, Narula S K, Zavodny P J, Chou C C. Characterization of interleukin-10 receptors on human and mouse cells. J Biol Chem 1993: 268: 21053-21059.
21. Moore K W, De Waal Malefyt R, Coffman R L, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001: 19: 683-765.
22. Bohnekoh B, Huerkamp C, Wevers A et al. Up-regulation of keratin 17 expression in human HaCaT keratinocytes by interferon-gamma. J Invest Dermatol 1995: 104: 58-61.
23. Chatelain R, Wollenberg A, Martin C et al. IL-10 inhibits ICAM-1 expression on human Langerhans cells but not on keratinocytes, dermal endothelial cells or fibroblasts. Arch Dermatol Res 1998: 290: 477-482.
24. Randow F, Syrbe U, Meisel C et al. Mechanisms of endotoxic desensitization: Involvement of interleukin 10 and transforming growth factor β. J Exp Med 1995: 181: 1887-1892.
25. Huhn R D, Radwanski E, O'Connell S M et al. Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. Blood 1996: 87: 699-705.
26. Mitra R S, Judge T A, Nestle F O, Turka L A, Nickoloff B J. Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10. Differential modulation of B7-1 (CD80) and B7-2 (CD86) expression. J Immunol 1995: 154: 2668-2677.